In prostate cancer cohorts using overall survival (OS) as an endpoint, high TMSB10 expression was associated with a trend toward poorer prognosis in GSE16560, ICGC, and TCGA cohorts (Figure 2A), though limited by small sample sizes and the slow progression of prostate cancer. Here, TMSB10 is linked to prostate carcinoma.